238P - Efficacy and toxicity of carboplatin/paclitaxel based chemoradiation for localized esophageal cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Oesophageal Cancer
Presenter Maria Qubtia
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors Y. Ishaq1, F. Badar2, M. Qubtia3, K. Munnawar1, A.S. Kazmi1
  • 1Medical Oncolgy, Shaukat Khanum Memorial Cancer Hospital and Reserch Centre (SKM), Lahore/PK
  • 2Cancer Registry And Clinical Data Management, Shaukat Khanum Memorial Cancer Hospital and Reserch Centre (SKM), Lahore/PK
  • 3Medical Oncolgy, Shaukat Khanum Memorial Cancer Hospital and Reserch Centre (SKM), 60700 - Lahore/PK

Abstract

Background

Tis study was carried out To establish the efficacy and safety of Carboplatin/paclitaxel combination for neoadjuvant and radical treatment of localized non-metastatic esophageal cancer in combination with radiation and surgery.

Methods

Retrospective review of case records of patients registered with oesophageal cancer between September 2013 and October 2014, yielded 139 patients who received treatment with carboplatin/paclitaxel based regimen. Out of these 102 patients with non-metastatic disease, who received radical chemoradiation (CRT) were included for toxicity and efficacy analysis, in the form of radiological response rate, R0 resection rate, progression free survival (PFS) and overall survival (OS). Impact of surgery vs. no surgery was assessed on PFS and OS.

Results

Males and females were 71(51.1%) and 68(48.9%) respectively, with squamous cell carcinoma being the predominant histology (92%). Majority of patient belonged to T3/4 and N1 stage. Grade III/IV thrombocytopenia, neutropenia, anaemia, febrile neutropenia requiring hospitalisation, non-hematologic toxicities were noted in 13(12.8%), 18(17.7%), 18(17.7%), 1(1%), 1(1%), patients respectively. Complete Radiological response, partial response, Stable disease, progressive disease were seen in 6(5.9%), 51(50%), 23(22.5%) 8(8.7%), respectively. Resection was done in 29 (28.4%). Complete and partial pathological response were seen 19(65.5%), 10 (34.4%), respectively. PFS at 40 and 80 weeks was 90%, 73%, respectively and OS at 80 weeks was 86%. PFS at 40 and 80 weeks was 100% and 90.5%, respectively with resection, while it was 86% and 65%, without resection (P value 0.015). OS at 40 and 80 weeks was 100% (both) with resection, while it was 96% and 79.5% weeks without resection. (P value 0.034).

Conclusions

Carboplatin/paclitaxel based CRT is effective with acceptable toxicity profile in treating localised oesophageal cancer as both as Radical CRT and as a part of multimodality therapy. For definitive results long term follow up and prospective analysis are required.

Clinical trial indentification

IRB exemption recieved on basis of it being the retrospective study and no direct inetraction was done with the patients .

Legal entity responsible for the study

Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

Funding

Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

Disclosure

All authors have declared no conflicts of interest.